Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

To contribute published user compound and/or population files, upload your files here: Upload Model Files

Searching Tips

You can use a * character as a wildcard at the end of a alphanumeric search term. The search term must start with at least one character before the wildcard. E.g., Rifam* will get you “Rifampicin” and “Rifampin”.
You can also use a * character as a wildcard in the middle of a alphanumeric search term. The search term must still start with at least one character before the wildcard. E.g., Rif*in will also get you “Rifampicin” and “Rifampin” .
You can also use a * character as a wildcard at the start of a alphanumeric search term. However you must use forward slashes to delimit the search term and use a point before the wildcard. E.g., /.*picin/ will only get you “Rifampicin”.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Found 137 Matches

V18 released Simcyp files for antiretroviral drugs

Model Files Publication

V18 released Simcyp files for antiretroviral drugs

Search Score: 2

TB Compound File Collection

Model Files Publication

V16 TB compound files and associated manuscript, as well as South African TB population file.

Search Score: 2

Dihydroartemisinin (DHA) from Artesunate

Model Files Publication

Brand Name(s) include: Camoquin (FDC with amodiaquine)

Disease: Malaria

Drug Class: Antimalarials

Related Drugs: DHA, Amodiaquine

Date Updated: March 2022

The model at-a-glance

Absorption Model	First-Order
Volume of Distribution	Full PBPK (Method 2) Note: Kp scalar used
Route of Elimination	UGT1A9 (50%); UGT2B7(50%)
Perpetrator DDI	CYP1A2 Inhibitor
Validation	One clinical study describing single dose exposure of DHA was used to verify the PBPK model. 100% of studies were within 2-fold, of which 100% were within 1.5-fold.
Limitations	The absorption model does not consider the formation of ‘DHA from artesunate’ mechanistically. Instead, an optimized ka and fa were applied to the DHA model to describe the observed plasma concentration-time curve of DHA. The remainder of the DHA model was identical to the DHA model which is described above. The model does not account for the differences in plasma fraction unbound observed in patients compared to healthy volunteers. Verification needed for perpetrator DDI assessment as literature data is unavailable at this time.
Updates in V19	Updated in vitro data Propranolol Papp: 30 cm/s x 106 Converted model to full PBPK with Vss predicted through Method 2 Updated retrograde clearance

Search Score: 2

Fexofenadine_RES_V23R1_Simcyp_20230401

Model Files Publication

Simcyp developed fexofenadine compound file. Compound summary included. This was developed as a research file and its current status and limitations are outlined in summary document.

Search Score: 2

Search the PBPK Model Repository

Searching Tips

V18 released Simcyp files for antiretroviral drugs

TB Compound File Collection

Dihydroartemisinin (DHA) from Artesunate

The model at-a-glance

Fexofenadine_RES_V23R1_Simcyp_20230401

Your Privacy